CN102892784B - 用于治疗乳腺癌的方法 - Google Patents

用于治疗乳腺癌的方法 Download PDF

Info

Publication number
CN102892784B
CN102892784B CN201180013038.7A CN201180013038A CN102892784B CN 102892784 B CN102892784 B CN 102892784B CN 201180013038 A CN201180013038 A CN 201180013038A CN 102892784 B CN102892784 B CN 102892784B
Authority
CN
China
Prior art keywords
seqidno
antibody
hpg
monoclonal antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180013038.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102892784A (zh
Inventor
J-F·弗洛克
L·扈胡
F·卡耶
D·朱伯特
F·霍兰德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute Of Health And Medicine
Centre National de la Recherche Scientifique CNRS
Laboratoires Servier SAS
Original Assignee
National Institute Of Health And Medicine
Centre National de la Recherche Scientifique CNRS
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institute Of Health And Medicine, Centre National de la Recherche Scientifique CNRS, Laboratoires Servier SAS filed Critical National Institute Of Health And Medicine
Publication of CN102892784A publication Critical patent/CN102892784A/zh
Application granted granted Critical
Publication of CN102892784B publication Critical patent/CN102892784B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201180013038.7A 2010-01-08 2011-01-07 用于治疗乳腺癌的方法 Expired - Fee Related CN102892784B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29361210P 2010-01-08 2010-01-08
US61/293,612 2010-01-08
PCT/EP2011/000048 WO2011083090A2 (en) 2010-01-08 2011-01-07 Methods for treating breast cancer

Publications (2)

Publication Number Publication Date
CN102892784A CN102892784A (zh) 2013-01-23
CN102892784B true CN102892784B (zh) 2016-06-22

Family

ID=43607948

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180013038.7A Expired - Fee Related CN102892784B (zh) 2010-01-08 2011-01-07 用于治疗乳腺癌的方法
CN201180013036.8A Expired - Fee Related CN102933603B (zh) 2010-01-08 2011-01-07 用于治疗胰腺癌的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180013036.8A Expired - Fee Related CN102933603B (zh) 2010-01-08 2011-01-07 用于治疗胰腺癌的方法

Country Status (15)

Country Link
US (2) US8900588B2 (ko)
EP (2) EP2542583B8 (ko)
JP (2) JP5572718B2 (ko)
KR (2) KR101468397B1 (ko)
CN (2) CN102892784B (ko)
AU (2) AU2011204654B2 (ko)
BR (2) BR112012016742A2 (ko)
CA (2) CA2786435C (ko)
EA (2) EA023722B1 (ko)
ES (2) ES2657246T3 (ko)
NZ (2) NZ601591A (ko)
PL (2) PL2542584T3 (ko)
SG (2) SG182334A1 (ko)
WO (2) WO2011083091A2 (ko)
ZA (2) ZA201205004B (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
US8136651B2 (en) * 2007-12-14 2012-03-20 The Procter & Gamble Company Method and apparatus for orienting articles
EA028515B1 (ru) * 2010-07-26 2017-11-30 Ле Лаборатуар Сервье Способы и композиции для терапии рака печени
US11078286B2 (en) 2015-09-20 2021-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
WO2017114973A1 (en) 2015-12-31 2017-07-06 Syncerus S.À R.L. Compositions and methods for assessing the risk of cancer occurrence
BR112018013272A2 (pt) 2015-12-31 2018-12-11 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer esofágico
BR112018013268A2 (pt) * 2015-12-31 2018-12-11 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer gástrico
KR102507685B1 (ko) * 2015-12-31 2023-03-08 프로가스트린 에 캔서스 에스.에이 알.엘. 난소암의 검출 및 치료를 위한 조성물 및 방법
JP6831135B2 (ja) * 2017-01-06 2021-02-17 レモネックス インコーポレイテッドＬｅｍｏｎｅｘ Ｉｎｃ． 転移性卵巣癌、子宮内膜癌もしくは乳癌の予防または治療用組成物
ES2926532T3 (es) * 2017-03-30 2022-10-26 Progastrine Et Cancers S A R L Composiciones y métodos para tratar el cáncer de pulmón
KR102317805B1 (ko) 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
WO2019055776A2 (en) 2017-09-14 2019-03-21 Rosser Charles COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING CXCL1 FUNCTION
CA3084687C (en) * 2017-12-05 2024-01-02 Progastrine Et Cancers S.A R.L. Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
AU2018381046A1 (en) 2017-12-08 2020-07-16 Ecs-Biotracker Sàrl Radiolabeled progastrin in cancer diagnosis
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
AU2019228339A1 (en) 2018-02-27 2020-09-10 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
WO2019177854A1 (en) 2018-03-13 2019-09-19 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
CN108864255B (zh) * 2018-06-21 2022-01-04 天津医科大学肿瘤医院 一种乳腺癌干细胞特异性结合多肽及其在制备治疗乳腺癌药物中的应用
WO2020160022A1 (en) 2019-01-28 2020-08-06 Rosser Charles J Compositions and methods for treatment of diseases involving cxcl1 function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032980A1 (en) * 2004-09-22 2006-03-30 Receptor Biologix, Inc. Monoclonal antibolies to progastrin
WO2008076454A1 (en) * 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
CN101460196A (zh) * 2006-05-22 2009-06-17 国立医学与健康研究所 在结肠癌治疗中的前胃泌素抑制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5922845A (en) * 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
NZ511550A (en) * 1997-05-12 2005-03-24 Aphton Corp CCK-B/gastrin receptor inhibitors for the treatment of tumors
AU2001241710B2 (en) 2000-02-25 2005-07-21 The Regents Of The University Of California Membrane estrogen receptor-directed therapy in breast cancer
FR2846426B1 (fr) 2002-10-28 2004-12-10 Bio Merieux Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
JPWO2008032876A1 (ja) 2006-09-15 2010-01-28 学校法人東海大学 Ｅｒ陰性およびｈｅｒ２陰性である乳癌の予防または治療剤およびそのスクリーニング方法
WO2008063479A2 (en) 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
JP2010540460A (ja) 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
PT2488551T (pt) * 2009-10-16 2018-10-31 Inst Nat Sante Rech Med Anticorpos monoclonais contra a progastrina e suas utilizações

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032980A1 (en) * 2004-09-22 2006-03-30 Receptor Biologix, Inc. Monoclonal antibolies to progastrin
CN101460196A (zh) * 2006-05-22 2009-06-17 国立医学与健康研究所 在结肠癌治疗中的前胃泌素抑制剂
WO2008076454A1 (en) * 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof

Also Published As

Publication number Publication date
WO2011083091A8 (en) 2012-08-09
ES2657245T3 (es) 2018-03-02
EA025329B1 (ru) 2016-12-30
KR101438362B1 (ko) 2014-09-05
CA2786479A1 (en) 2011-07-14
SG182331A1 (en) 2012-08-30
EP2542584B8 (en) 2017-12-13
KR101468397B1 (ko) 2014-12-04
CN102933603B (zh) 2016-01-20
CA2786479C (en) 2016-03-15
WO2011083091A2 (en) 2011-07-14
CA2786435C (en) 2017-01-17
JP6134141B2 (ja) 2017-05-24
ZA201205004B (en) 2013-09-25
EA023722B1 (ru) 2016-07-29
AU2011204654B2 (en) 2014-04-10
EA201200999A1 (ru) 2013-02-28
KR20130028050A (ko) 2013-03-18
AU2011204653B2 (en) 2014-04-10
EP2542583B8 (en) 2017-12-13
US8900588B2 (en) 2014-12-02
ZA201205003B (en) 2013-09-25
NZ601588A (en) 2014-07-25
CA2786435A1 (en) 2011-07-14
KR20120135401A (ko) 2012-12-13
EP2542584B1 (en) 2017-10-25
BR112012016742A2 (pt) 2018-05-15
US20110177062A1 (en) 2011-07-21
NZ601591A (en) 2015-01-30
WO2011083090A3 (en) 2011-10-06
SG182334A1 (en) 2012-08-30
EP2542584A2 (en) 2013-01-09
CN102933603A (zh) 2013-02-13
WO2011083090A2 (en) 2011-07-14
JP5572718B2 (ja) 2014-08-13
BR112012016820A2 (pt) 2023-11-28
EA201200998A1 (ru) 2013-02-28
JP2013516439A (ja) 2013-05-13
US20110171213A1 (en) 2011-07-14
EP2542583B1 (en) 2017-10-25
US9487582B2 (en) 2016-11-08
JP2013516438A (ja) 2013-05-13
AU2011204654A1 (en) 2012-07-26
AU2011204653A1 (en) 2012-07-26
CN102892784A (zh) 2013-01-23
PL2542583T3 (pl) 2018-04-30
EP2542583A2 (en) 2013-01-09
WO2011083091A3 (en) 2011-09-09
PL2542584T3 (pl) 2018-04-30
ES2657246T3 (es) 2018-03-02

Similar Documents

Publication Publication Date Title
CN102892784B (zh) 用于治疗乳腺癌的方法
CN102947337B (zh) 用于治疗结肠直肠癌的方法
CN102791735B (zh) 抗前胃泌素的单克隆抗体及其用途
CN103261224A (zh) 用于肝癌治疗的方法和组合物
TWI822822B (zh) 抗體-藥物結合物之用途
CN110475569A (zh) 通过施用抗her3抗体-药物偶联物实现的egfr-tki耐受性的非小细胞肺癌的治疗方法
WO2016026456A1 (en) Saccharide-based biomarkers and therapeutics
JP2017066156A (ja) 前立腺癌治療のための抗アルファ−ｖインテグリン抗体
US20210308208A1 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
CN104169301A (zh) 人生长激素受体拮抗剂抗体及其使用方法
US20210402003A1 (en) Methods of treating cancer with a combination of an anti-vegf antibody and an anti-tissue factor antibody-drug conjugate
CN1933851A (zh) 使用抗－α5β1抗体抑制癌细胞增殖
TWI844571B (zh) 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SERVIER LAB

Free format text: FORMER OWNER: BIOREALITES

Effective date: 20130417

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130417

Address after: Inside France

Applicant after: LES LABORATOIRES SERVIER

Applicant after: National Institute of Health and Medicine

Applicant after: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

Address before: French Suresnes

Applicant before: Byrotti

Applicant before: National Institute of Health and Medicine

Applicant before: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160622

Termination date: 20220107